The EGFR inhibitor gefitinib presented a low clinical benefit rate (CBR) and virtually no tumor response in patients with advanced breast cancer (ABC), regardless of whether their tumors were hormone receptor positive or hormone receptor negative.6 Here, EGFR is linked to neoplasm.